| Patient | Sonny Liston |
|---|---|
| Date of birth | 1932-05-08 |
| Identifiers | MRN HR-BX007-SYN-TD; SSN (made up) 000-07-8853 |
| Document date | 1969-09-22 |
| Author | Malcolm Achebe-Whitford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of blood pressure and drinking. [S]
Sonny Liston returns two weeks after a cold, for which he stopped an over-the-counter decongestant; his home readings came back down within two days and have averaged 124/78 mmHg over the past week. He takes amlodipine 10 mg and valsartan 160 mg and naltrexone 50 mg each morning. Mild ankle swelling after long runs in the heat goes by morning. He drinks three or four drinks on one or two evenings a week and has not had more than four on any day since starting naltrexone; the urge to keep going is much weaker. He saw the dentist about his molar. He wants to start sparring hard again. No thoughts of suicide. [S]
| Element | Detail |
|---|---|
| Home readings | Average 124/78 mmHg |
| Liver tests | AST 31, ALT 30, GGT 54 U/L |
| AUDIT-C | 4 |
| Vaccine today | Second hepatitis B dose |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Mild ankle swelling after long runs, gone by morning; no chest pain or palpitations |
| Ears, nose, mouth, and throat | Negative | Cold symptoms gone |
| Gastrointestinal | Negative | No nausea on naltrexone |
| Psychiatric | Negative | Mood good; no thoughts of suicide |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morning | One tablet each morning | Oral route | 1969-06-23 to 1969-07-21 | completed | S |
| Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morning | One tablet each morning | Oral route | 1969-07-21 | active | S |
| Naltrexone 50 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 1969-07-21 | active | S |
| Pseudoephedrine 30 mg oral tablet, bought over the counter as a cold tablet, two tablets up to four times a day | Two tablets up to four times a day | Oral route | 1969-09-05 to 1969-09-08 | stopped | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every six hours as needed for aches, no more than four tablets (2 g) a day because he drinks | One or two tablets every six hours as needed; no more than four tablets a day | Oral route | 1969-09-08 to 1969-09-15 | completed | S |
| Saline nasal spray 0.65%, two sprays in each nostril as needed | Two sprays in each nostril as needed | Nasal route | 1969-09-08 to 1969-09-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1969-09-22 | Body height | 185 | cm | S |
| 1969-09-22 | Body weight | 97.2 | kg | S |
| 1969-09-22 | Body mass index (BMI) [Ratio] | 28.4 | kg/m2 | S |
| 1969-09-22 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1969-09-22 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1969-09-22 | Heart rate | 56 | /min | S |
| 1969-09-22 | Respiratory rate | 14 | /min | S |
| 1969-09-22 | Body temperature | 36.6 | Cel | S |
| 1969-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1969-09-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-40 U/L | Normal | S |
| 1969-09-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 1969-09-22 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 54 | U/L | 8-61 U/L | Normal | S |
| 1969-09-22 | Total score [AUDIT-C] | 4 | {score} | S |
Vital signs recorded on 1969-09-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/78 mmHg (average of two); pulse 56; weight 97.2 kg |
| Cardiovascular | Regular rhythm; trace ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| High blood pressure readings at a first visit (154/98 mmHg, average of two readings with a large cuff), without a diagnosis of hypertension; out-of-office confirmation needed | resolved | confirmed | R03.0 | S — Synthetic presenting finding; resolved into the diagnosis at the consultation visit when ambulatory monitoring confirmed hypertension. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (daytime average 146/94 mmHg, nighttime 132/84 mmHg), with mild concentric left ventricular hypertrophy on echocardiography and normal kidney function and urine albumin | active | confirmed | I10 | S — Synthetic modern diagnosis; no hypertension is documented in his life. |
| Alcohol use disorder, moderate (four DSM-5-TR criteria: drinking more than intended, unsuccessful efforts to cut down, craving, and continued drinking despite its effect on his training, blood pressure and liver tests); AUDIT 16 | active | confirmed | F10.20 | S — Synthetic modern diagnosis by interview, anchored to the description of heavy drinking; not a historical diagnosis. |
| Personal history of physical abuse in childhood (beaten regularly by his father), with heavy field work from the age of eight | active | confirmed | Z62.810 | S — Synthetic coding of the documented childhood history; physical abuse only. |
| Does not read or write (no schooling as a child); prefers spoken explanations, pictures and demonstrations | active | confirmed | Z55.0 | S — Synthetic coding of the documented literacy, recorded so that care is adapted. |
| Acute viral upper respiratory infection (common cold) for four days, with blood pressure raised to 158/98 mmHg by an over-the-counter pseudoephedrine cold tablet he could not read the label of; resolved | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, large cuff, average of two readings), weight and BMI, heart sounds | Every visit | Completed today | 126/78 mmHg; weight 97.2 kg |
| Examination | Out-of-office blood pressure (ambulatory or home monitoring) | At diagnosis and after each treatment change | Completed today | Home average 124/78 mmHg by voice message |
| Laboratory | Potassium, creatinine and eGFR | Baseline; two to four weeks after starting an ARB; then every six months on an ARB | Up to date | Potassium 4.4 and creatinine 1.1 two months ago; next in about four months |
| Examination | Fundoscopic examination | Yearly | Up to date | Normal at the preventive visit |
| Survey | Cardiovascular risk estimate | Yearly | Up to date | Low at the preventive visit; statin not indicated |
| Medication safety | Antihypertensive tolerance (ankle edema, dizziness) and adherence by teach-back | Each follow-up and each dose change | Completed today | Trace ankle edema after long runs; no dizziness; teach-back correct |
| Referral | Fitness to compete (AHA/ACC athlete statement) | At diagnosis and before returning to competition | Completed today | Controlled; letter to the commission physician for clearance |
| Survey | Drinking (AUDIT-C, drinks per week, drinking days) | Every follow-up during treatment; full AUDIT at about four months | Completed today | AUDIT-C 4; about 7 drinks a week, no day above 4 |
| Laboratory | Liver tests (AST, ALT, GGT) | Baseline; about two months after starting naltrexone or cutting down; then as indicated | Completed today | AST 31, ALT 30, GGT 54 U/L, two months after starting naltrexone |
| Medication safety | Naltrexone: nausea, liver tests, and opioid-blockade wallet card | Each follow-up after starting | Completed today | No nausea; liver tests improving; carries the wallet card |
| Survey | Suicide-risk review (structured questions) and safety plan | Every visit | Completed today | No thoughts of suicide |
| Self-management | Health literacy: teach-back, picture card, read-aloud consent, voice reminders | Every visit | Completed today | Teach-back of the medicines to avoid correct; the pharmacist now reads labels to him |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (Black HR, et al.) (2015); The Healthcare Professional's Core Resource on Alcohol (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024); Adult Immunization Schedule by Age (2026)
Follow-up: Four-month review in four weeks with the full AUDIT, GGT and PHQ-9, and the influenza vaccine. Call 988 or the clinic at any time if thoughts of suicide arise. Next scheduled visit 1969-10-20: four-month review: blood pressure at goal, AUDIT, and the plan ahead. [S]